Ensoma, Inc. — Form D/A
Ensoma, Inc. of Boston, MA, a company, filed a Form D amendment with the SEC on 2023-05-23. The offering totals $129.0M, of which $129.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-05-23
- Form: D/A
- Accession: 0001846902-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $129.0M
- Amount sold: $129.0M
- Investors: 22
- Date of first sale: 2022-12-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-470026
Issuer
- Name: Ensoma, Inc.
- CIK: 0001846902
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 451 D Street, Suite 600, Boston, MA, 02210
- Phone: 617-272-2400
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Mark M Chin | Director | Boston, MA |
| Kouki M Harasaki | Director | Boston, MA |
| Emile Nuwaysir | Director | Boston, MA |
| Kush M Parmar | Director | Boston, MA |
| Albert M Seymour | Director | Boston, MA |
| Nihal Sinha | Director | Encinitas, CA |
| Paula Soteropoulos | Director | Boston, MA |
| Emile Nuwaysir | Executive Officer | Boston, MA |
| Stephen Knight | Director | NEW HAVEN, CT |
| Kush Parmar | Director | San Francisco, CA |
| Kush Parmar | Executive Officer | San Francisco, CA |
| Albert Seymour | Director | Boston, MA |
Other filings by this issuer (2)
More